Adaptimmune Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch ADAPY and buy or sell other stocks, ETFs, and their options commission-free!About ADAPY
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8.
CEOChristopher James Hill
CEOChristopher James Hill
Employees506
Employees506
HeadquartersAbingdon, Oxfordshire
HeadquartersAbingdon, Oxfordshire
Founded2014
Founded2014
Employees506
Employees506
ADAPY Key Statistics
Market cap13.04M
Market cap13.04M
Price-Earnings ratio-0.07
Price-Earnings ratio-0.07
Dividend yield—
Dividend yield—
Average volume2.02M
Average volume2.02M
High today$0.0567
High today$0.0567
Low today$0.044
Low today$0.044
Open price$0.0441
Open price$0.0441
Volume1.48M
Volume1.48M
52 Week high$0.685
52 Week high$0.685
52 Week low$0.0202
52 Week low$0.0202
Stock Snapshot
Adaptimmune Therapeutics(ADAPY) stock is priced at $0.05, giving the company a market capitalization of 13.04M. It carries a P/E multiple of -0.07.
As of 2025-12-06, Adaptimmune Therapeutics(ADAPY) stock has fluctuated between $0.04 and $0.06. The current price stands at $0.05, placing the stock +11.8% above today's low and -13.2% off the high.
Adaptimmune Therapeutics(ADAPY) shares are trading with a volume of 1.48M, against a daily average of 2.02M.
During the past year, Adaptimmune Therapeutics(ADAPY) stock moved between $0.02 at its lowest and $0.69 at its peak.
During the past year, Adaptimmune Therapeutics(ADAPY) stock moved between $0.02 at its lowest and $0.69 at its peak.